Relay Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview

Relay Therapeutics

30/04/2024 22:50

* Relay Therapeutics Inc  RLAY.OQ   RLAY.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 2 for
the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 61.3% decrease in revenue to $87.5 thousand from $226 thousand
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Relay Therapeutics Inc
is for
a loss of 71 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Relay
Therapeutics Inc is $24.00​, above​ its last closing price
of $6.59. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.69       -0.73      -0.67     Beat    8
 Jan. 1 2023   -0.82       -0.83      -0.54     Beat    35
 Jun. 30 2023  -0.84       -0.82      -0.81     Beat    0.7​
 Jan. 1 0001   -0.66       -0.69      -0.78     Missed  -12.8
 ​​Jan.        -0.71       -0.70      -0.56     Beat    20.3
 1 0001                                                 
 Jan. 1 0001   -0.72       -0.71      -0.76     Missed  -7.7​
 Jun. 30 2022  -0.63       -0.63      -0.71     Missed  -13
 Jan. 1 0001   -0.62       -0.62      -0.57     Beat    7.8
 This summary was machine generated April 30 at 21:50 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)